Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS)

Toxicology

Volumn 234, Issue 1-2, 2007, Pages 21-33

  Chang, Shu Ching ^a   Thibodeaux, Julie R ^b   Eastvold, Mary L ^c   Ehresman, David J ^a   Bjork, James A ^d   Froehlich, John W ^e   Lau, Christopher S ^b   Singh, Ravinder J ^c   Wallace, Kendall B ^d   Butenhoff, John L ^a  

^a 3M COMPANY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e Pace Analytical   (United States)

Author keywords

Analog method; Equilibrium dialysis; Negative bias; Perfluorooctanesulfonate (PFOS); Rats; Thyroid hormones

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CARRIER PROTEIN; FATTY ACID; LIVER ENZYME; MALATE DEHYDROGENASE (DECARBOXYLATING); MESSENGER RNA; PERFLUOROOCTANESULFONIC ACID; THYROTROPIN; THYROXINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; EQUILIBRIUM DIALYSIS; FEMALE; HISTOLOGY; HORMONE DETERMINATION; HORMONE RESPONSE; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RNA TRANSCRIPTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADMINISTRATION, ORAL; ALKANESULFONIC ACIDS; ANIMALS; CHEMILUMINESCENT MEASUREMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROCARBONS; HEMODIALYSIS SOLUTIONS; LABORATORY TECHNIQUES AND PROCEDURES; LIVER; MALATE DEHYDROGENASE; OLEIC ACID; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TANDEM MASS SPECTROMETRY; THYROTROPIN; THYROXINE;

RATTUS;

EID: 34047167383     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.01.020     Document Type: Article

References (70)

1. Ankley G.T., Kuehl D.W., Kahl M.D., Jensen K.M., Butterworth B.C., and Nichols J.W. Partial life-cycle toxicity and bioconcentration modeling of perfluorooctanesulfonate in the northern leopard frog (Rana pipiens). Environ. Toxicol. Chem. 23 (2004) 2745-2755
2. Berthiaume J., and Wallace K.B. Perfluorooctanoate, perfluorooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett. 129 (2002) 23-32
3. Bogazzi F., Bartalena L., Brogioni S., Burelli A., Grasso L., Dell'Unto E., Manetti L., and Martino E. L-Thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRbeta. Mol. Cell Endocrinol. 134 (1997) 23-31
4. Burtis C.A., and Ashwood E.R. Tietz Textbook of Clinical Chemistry (1994), W.B. Saunders, Philadelphia
5. Butenhoff J.L., Olsen G.W., and Pfahles-Hutchens A. The applicability of biomonitoring data for perfluorooctanesulfonate (PFOS) to the environmental public health continuum. Environ. Health Perspect. 114 (2006) 1776-1782
6. Cai Y., Nelson B.D., Li R., Luciakova K., and DePierre J.W. Thyromimetic action of the peroxisome proliferators clofibrate, perfluorooctanoic acid, and acetylsalicylic acid includes changes in mRNA levels for certain genes involved in mitochondrial biogenesis. Arch. Biochem. Biophys. 325 (1996) 107-112
7. Chopra I.J. Clinical review 86: Euthyroid sick syndrome: is it a misnomer?. J. Clin. Endocrinol. Metab. 82 (1997) 329-334
8. Christofides N.D., Wilkinson E., Stoddart M., Ray D.C., and Beckett G.J. Assessment of serum thyroxine binding capacity-dependent biases in free thyroxine assays. Clin. Chem. 45 (1999) 520-525
9. Christofides N.D., Wilkinson E., Stoddart M., Ray D.C., and Beckett G.J. Serum thyroxine binding capacity-dependent bias in an automated free thyroxine assay. J. Immunoassay 20 (1999) 201-221
10. ® Total T4 Veterinary Application, Rat Serum T4. Technical bulletin ZV103 A, March 24, 1993, Diagnotic Products Corporation, Los Angeles, CA.
11. Ehresman D.J., Froehlich J.W., Olsen G.W., Changa S.-C., and Butenhoff J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ. Res. 103 (2007) 176-184
12. Ekins R. Labelled analogue "free" thyroxine assays: the unanswered questions. Lancet 2 (1983) 1196
13. Ekins R. Validity of analog free thyroxin immunoassays. Clin. Chem. 33 (1987) 2137-2144
14. Ekins R. Direct determination of free thyroxin in undiluted serum by equilibrium dialysis/radioimmunoassay. Clin. Chem. 35 (1989) 510-512
15. Ekins R. Effect of thyroid hormone-binding proteins and fatty acids on modified analog assays of FT4 and FT3 in serum. Clin. Chem. 35 (1989) 708-710
16. Ekins R. Measurement of free hormones in blood. Endocr. Rev. 11 (1990) 5-24
17. Ekins R. Analytic measurements of free thyroxine. Clin. Lab. Med. 13 (1993) 599-630
18. Ekins R. Free triiodothyronine in nonthyroidal illness. Clin. Chem. 40 (1994) 162-163
19. Ekins R.P., Jackson T., Edwards P., Salter C., and Ogier I. Euthyroid sick syndrome and free thyroxine assay. Lancet 322 (1983) 402-404
20. Fisher J.W., Campbell J., Muralidhara S., Bruckner J.V., Ferguson D., Mumtaz M., Harmon B., Hedge J.M., Crofton K.M., Kim H., and m Almekinder T.L. Effect of PCB 126 on hepatic metabolism of thyroxine and perturbations in the hypothalamic-pituitary-thyroid axis in the rat. Toxicol. Sci. 90 (2006) 87-95
21. Fuentes S., Colomina M.T., Rodriguez J., Vicens P., and Domingo J.L. Interactions in developmental toxicology: Concurrent exposure to perfluorooctane sulfonate (PFOS) and stress in pregnant mice. Toxicol. Lett. 164 (2006) 81-89
22. Geer B.W., Krochko D., Oliver M.J., Walker V.K., and Williamson J.H. A comparative study of the NADP-malic enzymes from Drosophila and chick liver. Comp. Biochem. Physiol. 65 (1980) 25-34
23. Giesy J.P., and Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35 (2001) 1339-1342
24. Gutshall D.M., Pilcher G.D., and Langley A.E. Mechanism of the serum thyroid hormone lowering effect of perfluoro-n-decanoic acid (PFDA) in rats. J. Toxicol. Environ. Health 28 (1989) 53-65
25. Hansen K.J., Clemen L.A., Ellefson M.E., and Johnson H.O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35 (2001) 766-770
26. Harada K., Saito N., Inoue K., Yoshinaga T., Watanabe T., Sasaki S., Kamiyama S., and Koizumi A. The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years. J. Occup. Health 46 (2004) 141-147
27. Harland W.A., and Orr J.S. The effect of clofibrate on thyroxine metabolism. In: Harland W.A., and Orr J.S. (Eds). Thyroid Hormone Metabolism (1974), Academic Press, New York 65-88
28. Hertz R., Aurbach R., Hashimoto T., and Bar-Tana J. Thyromimetic effect of peroxisomal proliferators in rat liver. Biochem. J. 274 Pt 3 (1991) 745-751
29. Hertz R., Kalderon B., and Bar-Tana J. Thyromimetic effect of peroxisome proliferators. Biochimie 75 (1993) 257-261
30. Hertz R., Nikodem V., Ben-Ishai A., Berman I., and Bar-Tana J. Thyromimetic mode of action of peroxisome proliferators: activation of "malic" enzyme gene transcription. Biochem. J. 319 Part 1 (1996) 241-248
31. Ijpenberg A., Jeannin E., Wahli W., and Desvergne B. Polarity and specific sequence requirement of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. The functional analyses of the malic enzyme gene PPAR response element. J. Biol. Chem. 272 (1997) 20108-20117
32. Ikeda T., Aiba K., Fukuda K., and Tanaka M. The induction of peroxisome proliferation in rat liver by perfluoinated fatty acids, metabolically inert derivatives of fatty acids. J. Biochem. 98 (1985) 475-482
33. Inoue K., Okada F., Ito R., Kato S., Sasaki S., Nakajima S., Uno A., Saijo Y., Sata F., Yoshimura Y., Kishi R., and Nakazawa H. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ. Health Perspect. 112 (2004) 1204-1207
34. Jaume J.C., Mendel C.M., Frost P.H., Greenspan F.S., and Laughton C.W. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. Thyroid 6 (1996) 79-83
35. Johnson J.D., Gibson S.J., and Ober R.E. Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam. Appl. Toxicol. 4 (1984) 972-976
36. Kerstner-Wood, C., Coward, L., Gorman, G., 2003. Protein binding of perfluorobutane sulfonate, perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanote to plasma (human, rat, and monkey), and various human-derived plasma protein fractions. Southern Research Institute Study No. 9921.7. USEPA Administrative Record AR-226-1354.
37. Kluanig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., and Fenner-Crisp P.A. PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33 (2003) 655-780
38. Laji K., Rhidha B., John R., Lazarus J., and Davies J.S. Abnormal serum free thyroid hormone levels due to heparin administration. QJM - Int. J. 94 (2001) 471-473
39. Larsen P.R., Kronenberg H.M., Melmed S., and Polonsky K.S. Williams Textbook of Endocrinology. 10th ed. (2003), Saunders, Philadelphia
40. Lau C., Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., Stanton M.E., Butenhoff J.L., and Stevenson L.A. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol. Sci. 74 (2003) 382-392
41. In: Loeb W.F., and Quimby F.W. (Eds). The Clinical Chemistry of Laboratory Animals. second ed. (1999), Taylor and Francis, Philadelphia
42. Luebker D.J., Hansen K.J., Bass N.M., Butenhoff J.L., and Seacat A.M. Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology 176 (2002) 175-185
43. Luebker D.J., York R.G., Hansen K.J., Moore J.A., and Butenhoff J.L. Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-response, and biochemical and pharamacokinetic parameters. Toxicology 215 (2005) 149-169
44. Martin J.W., Smithwick M.M., Braune B.M., Hoekstra P.F., Muir D.C., and Mabury S.A. Identification of long-chain perfluorinated acids in biota from the Canadian Arctic. Environ. Sci. Technol. 38 (2004) 373-380
45. Mendel C.M., Frost P.H., and Cavalieri R.R. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin. J. Clin. Endocrinol. Metab. 63 (1986) 1394-1399
46. Mendel C.M., Frost P.H., Kunitake S.T., and Cavalieri R.R. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J. Clin. Endocrinol. Metab. 65 (1987) 1259-1264
47. Midgley J.E. Direct and Indirect free thyroxine assay methods: theory and practice. Clin. Chem. 47 (2001) 1353-1363
48. Nelson J.C., Nayak S.S., and Wilcox R.B. Variable underestimates by serum free thyroxine (T4) immunoassays of free T4 concentrations in simple solutions. J. Clin. Endocrinol. Metab. 79 (1994) 1373-1375
49. Nelson J.C., and Weiss R.M. The effect of serum dilution on free thyroxine (T4) concentration in the low T4 syndrome of nonthyroidal illness. J. Clin. Endocrinol. Metab. 61 (1985) 239-246
50. Nelson J.C., Weiss R.M., and Wilcox R.B. Underestimates of serum free thyroxine (T4) concentrations by free T4 immunoassays. J. Clin. Endocrinol. Metab. 79 (1994) 76-79
51. OECD, Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and its Salts, 2002. Organisation for Economic Cooperation and Development, Paris, France.
52. Okabayashi T., Takeda K., Kawada M., Kubo Y., Nakamura S., Chikamori K., Terao N., and Hashimoto K. Free thyroxine concentrations in serum measured by equilibrium dialysis in chronic renal failure. Clin. Chem. 42 (1996) 1616-1620
53. Olsen G.W., Church T.R., Larson E.B., van Belle G., Lundberg J.K., Hansen K.J., Burris J.M., Mandel J.H., and Zobel L.R. Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere 54 (2004) 1599-1611
54. Olsen G.W., Church T.R., Miller J.P., Burris J.M., Hansen K.J., Lundberg J.K., Armitage J.B., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., O'Neill E.M., Mandel J.H., and Zobel L.R. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ. Health Perspect. 111 (2003) 1892-1901
55. Olsen G.W., Burris J.M., Burlew M.W., and Mandel J.H. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45 (2003) 260-270
56. Olsen G.W., Huang H.Y., Helzlsouer K.J., Hansen K.J., Butenhoff J.L., and Mandel J.H. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ. Health Perspect. 113 (2005) 539-545
57. Oppenheimer J.H., Silva E., Schwartz H.L., and Surks M.I. Stimulation of hepatic mitochondrial glycerophosphate dehydrogenase and malic enzyme by l-triiodothyronine. J. Clin. Invest. 59 (1977) 517-527
58. Ravel R. Clinical Laboratory Medicine: Clinical Application of Laboratory Data (1995), Mosby-Year Book Inc, Saint Louis
59. Reimers T.J. Hormones. In: Loeb W.F., and Quimby F.W. (Eds). The Clinical Chemistry of Laboratory Animals. second ed. (1999), Taylor and Francis, Philadelphia 468 Chapter 14
60. Sapin R. Serum thyroxine binding capacity-dependent bias in five free thyroxine immunoassays: assessment with serum dilution experiments and impact on diagnostic performance. Clin. Biochem. 34 (2001) 367-371
61. Sapin R., and d'Herbomez M. Free thyroxine measured by equilibrium dialysis and nine immunoassays in sera with various serum thyroxine-binding capacities. Clin. Chem. 49 (2003) 1531-1535
62. Sapin R., and Schlienger J.L. Thyroxine (T4) and tri-iodothyronine (T3) determinations: techniques and value in the assessment of thyroid function. Ann. Biol. Clin. (Paris) 61 (2003) 411-420
63. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., and Butenhoff J.L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183 (2003) 117-131
64. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., and Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 68 (2002) 249-264
65. Sohlenius A.-K., Eriksson A.M., Högström C., Kimland M., and DePierre J.W. Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid β-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver. Pharmacol. Toxicol. 72 (1993) 90-93
66. Spector A.A. Fatty acid binding to plasma albumin. J. Lipid Res. 16 (1975) 165-179
67. Stevenson H.P., Archbold G.P.R., Johnston P., Young I.S., and Sheridan B. Misleading serum free thyroxine results during low molecular weight heparin treatment. Clin. Chem. 44 (1998) 1002-1007
68. Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., Barbee B.D., Richards J.H., Butenhoff J.L., Stevenson L.A., and Lau C. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol. Sci. 74 (2003) 369-381
69. Thomford, P.J., 2002. Final report: 104-week dietary chronic toxicity and carcinogenicity with perfluroorctanesulfonic acid postassium salt (PFOS; T-6295) in rats. Covance Laboratory Inc, Madison WI.
70. Wilkins T.A., Midgley J.E., and Giles A.F. Treatment with heparin and results for free thyroxine: an in vivo or an in vitro effects?. Clin. Chem. 28 (1982) 2441-2443